These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 9247562

  • 1. Gene transfer of a hybrid interleukin-1 beta gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo.
    Björkdahl O, Wingren AG, Hedhund G, Ohlsson L, Dohlsten M.
    Cancer Immunol Immunother; 1997 Jul; 44(5):273-81. PubMed ID: 9247562
    [Abstract] [Full Text] [Related]

  • 2. Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release.
    Wingren AG, Björkdahl O, Labuda T, Björk L, Andersson U, Gullberg U, Hedlund G, Sjögren HO, Kalland T, Widegren B, Dohlsten M.
    Cell Immunol; 1996 May 01; 169(2):226-37. PubMed ID: 8620550
    [Abstract] [Full Text] [Related]

  • 3. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O, Dohlsten M, Sjögren HO.
    Cancer Gene Ther; 2000 Oct 01; 7(10):1365-74. PubMed ID: 11059695
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.
    García-Hernández ML, Hernández-Pando R, Gariglio P, Berumen J.
    Immunology; 2002 Feb 01; 105(2):231-43. PubMed ID: 11872099
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.
    Seo N, Hayakawa S, Takigawa M, Tokura Y.
    Immunology; 2001 Aug 01; 103(4):449-57. PubMed ID: 11529935
    [Abstract] [Full Text] [Related]

  • 6. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
    Kim TS, Russell SJ, Collins MK, Cohen EP.
    Int J Cancer; 1992 May 08; 51(2):283-9. PubMed ID: 1533203
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumour effects of interleukin 1 beta: in vivo induction of immunity to B16 melanoma, a non-immunogenic tumour.
    Neville ME, Pezzella KM.
    Cytokine; 1994 May 08; 6(3):310-7. PubMed ID: 8054488
    [Abstract] [Full Text] [Related]

  • 8. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X, Zhang W, Wang J, Zhang M, Huang X, Hamada H, Chen W.
    Immunology; 1999 Aug 08; 97(4):616-25. PubMed ID: 10457215
    [Abstract] [Full Text] [Related]

  • 9. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.
    Duguay D, Mercier F, Stagg J, Martineau D, Bramson J, Servant M, Lin R, Galipeau J, Hiscott J.
    Cancer Res; 2002 Sep 15; 62(18):5148-52. PubMed ID: 12234977
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo.
    McKenzie RC, Oran A, Dinarello CA, Sauder DN.
    Anticancer Res; 1996 Sep 15; 16(1):437-41. PubMed ID: 8615650
    [Abstract] [Full Text] [Related]

  • 11. Effect of ultraviolet-inducible cytokines on melanoma growth in vivo: stimulation of melanoma growth by interleukin-1 and -6.
    Mckenzie RC, Park ES, Brown WR, Shivji GS, Sauder DN.
    Photodermatol Photoimmunol Photomed; 1994 Apr 15; 10(2):74-9. PubMed ID: 8043388
    [Abstract] [Full Text] [Related]

  • 12. Gene electrotransfer of IL-2 and IL-12 plasmids effectively eradicated murine B16.F10 melanoma.
    Komel T, Bosnjak M, Kranjc Brezar S, De Robertis M, Mastrodonato M, Scillitani G, Pesole G, Signori E, Sersa G, Cemazar M.
    Bioelectrochemistry; 2021 Oct 15; 141():107843. PubMed ID: 34139572
    [Abstract] [Full Text] [Related]

  • 13. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo.
    Werthmöller N, Frey B, Rückert M, Lotter M, Fietkau R, Gaipl US.
    Int J Hyperthermia; 2016 Oct 15; 32(1):23-30. PubMed ID: 26754406
    [Abstract] [Full Text] [Related]

  • 14. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.
    J Gene Med; 1999 Oct 15; 1(6):400-6. PubMed ID: 10753065
    [Abstract] [Full Text] [Related]

  • 15. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE, Zachary DT, Osband ME.
    Int J Cancer; 1995 May 16; 61(4):580-6. PubMed ID: 7759164
    [Abstract] [Full Text] [Related]

  • 16. Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.
    Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM.
    Immunology; 2013 Mar 16; 138(3):280-92. PubMed ID: 23198850
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C.
    Cancer Res; 2006 Jun 15; 66(12):6395-404. PubMed ID: 16778218
    [Abstract] [Full Text] [Related]

  • 18. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
    Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL.
    Immunology; 2007 Mar 15; 120(3):412-23. PubMed ID: 17163960
    [Abstract] [Full Text] [Related]

  • 19. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
    Song S, Wang Y, Wang J, Lian W, Liu S, Zhang Z, Liu F, Wei L.
    Eur J Cancer; 2012 Sep 15; 48(14):2252-9. PubMed ID: 22230748
    [Abstract] [Full Text] [Related]

  • 20. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S, Hatzinisiriou I, Ralph SJ.
    Immunol Cell Biol; 2003 Dec 15; 81(6):459-71. PubMed ID: 14636243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.